The Stephens Inc. AR Has $595,000 Stake in Illumina, Inc. (ILMN)

The Stephens Inc. AR Has $595,000 Stake in Illumina, Inc. (ILMN)

Stephens Inc. AR reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 24.9% during the third quarter, Holdings Channel reports. The institutional investor owned 3,275 shares of the life sciences company’s stock after selling 1,086 shares during the period. Stephens Inc. AR’s holdings in Illumina were worth $595,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ILMN. Baillie Gifford & Co. boosted its position in shares of Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock worth $2,613,182,000 after buying an additional 682,010 shares in the last quarter. Capital Research Global Investors boosted its position in shares of Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock worth $1,836,882,000 after buying an additional 1,910,346 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Illumina by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,877,155 shares of the life sciences company’s stock worth $704,324,000 after buying an additional 41,792 shares in the last quarter. Capital World Investors boosted its position in shares of Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock worth $205,376,000 after buying an additional 1,003,000 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its position in shares of Illumina by 14.3% in the second quarter. BlackRock Investment Management LLC now owns 1,181,457 shares of the life sciences company’s stock worth $165,853,000 after buying an additional 147,381 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.47% on Wednesday, reaching $161.23. The company’s stock had a trading volume of 1,012,377 shares. The company’s 50 day moving average is $135.27 and its 200-day moving average is $151.62. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $186.88. The firm has a market cap of $23.68 billion, a price-to-earnings ratio of 54.10 and a beta of 1.16.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.10. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The company earned $607 million during the quarter, compared to the consensus estimate of $628.06 million. During the same period in the prior year, the company earned $0.80 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities research analysts expect that Illumina, Inc. will post $3.32 EPS for the current year.

A number of equities research analysts have commented on the company. Deutsche Bank AG restated a “hold” rating and set a $160.00 price objective on shares of Illumina in a research report on Wednesday. Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Tuesday, December 13th. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $141.42 price objective for the company. in a research report on Tuesday, December 13th. Barclays PLC set a $142.00 price objective on Illumina and gave the stock an “equal weight” rating in a research report on Tuesday, October 11th. Finally, Leerink Swann assumed coverage on Illumina in a research report on Thursday, November 10th. They set a “market perform” rating and a $145.00 price objective for the company. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $151.96.

In other news, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $123.42, for a total transaction of $74,052.00. Following the completion of the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at $2,106,162.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Omead Ostadan sold 3,000 shares of the company’s stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $133.30, for a total value of $399,900.00. Following the transaction, the executive vice president now directly owns 51,492 shares of the company’s stock, valued at $6,863,883.60. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Related posts

Leave a Comment